New Report Urges FDA Clinical Trial Reform

Today, the Government
Accountability Project (GAP) is releasing a new "white
paper" report, The
ABCs of Drug Safety: Accountability, Balance, and Citizen Empowerment,
which focuses on the severe problems with the current system for conducting and
regulating clinical trials. The report details the urgent need for
reform.

Click here to read a copy of the new report's
executive summary: https://www.whistleblower.org/doc/2008/ABCExecSum.pdf

Click here to read a copy of the new report: https://www.whistleblower.org/doc/2008/ABCFinal040709.pdf

Mark Cohen, GAP Executive Director and coauthor of the
report, stated "The current clinical trial reform process is rife with
conflicts of interest that put trial subjects at risk and produce suspect data
on drug safety and efficacy. Making matters worse, federal oversight is wholly
inadequate."

The report examines a number of recent and historical
controversies with regard to clinical trial studies and institutional review
boards (IRBs) - analyzing how major players at both the corporate and FDA
levels have too often failed to perform their critical duties to safeguard
human health. More importantly, GAP's report proposes constructive
reforms to the overall process, calling for the empowerment of trial
participants, whistleblower protections for employees staffing trials and IRBs,
removal of financial conflicts of interest between parties, and trial biases in
favor of approval of proposed drugs. Specifically, our report advocates for:

• Greater
  Whistleblower Protections for all Involved Parties:
  Stronger anti-retaliation measures for those with evidence of wrongdoing
  and threats to public health are essential to weed out bad faith parties.
• Legal
  Recourse for Injured Trial Participants: The Supreme
  Court held that state court personal injury lawsuits against medical
  device makers are preempted if the product is FDA approved. Congress must
  intervene on patient's behalves, and ensure adequate protections to
  trial participants of such devices.
• Federal
  Government Protections of all Clinical Trial Participants: An estimated 40 percent of
  studies and over five million research participantsare leftuncovered each year.
• Legislative
  Reform of IRBs: A number of structural, financial,
  procedural, and regulatory gaps plague the IRB system.
• Greater Monitoring of IRB "Informed Consent" Practices: The
  current IRB system focuses almost exclusively on the review of consent
  forms. Yet, the law does not require IRBs to regularly observe consent
  interviews or the conduct of study protocols.
• "Non-Inferiority Trial" Reform: The
  FDA currently permits the drug industry to prove the efficacy of a new
  drug by comparing it to a previously approved drug for the same
  indication, even where comparison to a placebo would not endanger the
  subject. Rather than requiring the new drug to be superior to the
  comparator drug, if the new drug is within a margin of inferiority the FDA
  deems acceptable, the agency will approve it. Approval of such a drug adds
  no value for patients but it does provide a mega-dollar benefit to drug
  companies.

IRB protocols have been a hot topic in the news. Two
weeks ago, it was uncovered at a House of Representatives hearing that the
Government Accountability Office, as part of a sting operation, created
multiple fake companies and drugs, submitted them for approval using three
third-party IRBs, and successfully received permission to begin clinical trial
use in patients. Also two weeks ago, the FDA released a progress report
regarding its Human Subject Protection and Bioresearch Monitoring Initiative. While some of its recommendations
represent progress, GAP still identifies major gaps to public safety.

"The FDA system of ensuring drug safety is a
work-in-progress," stated Sheila Fleischhacker, author of the report.
"Some of the FDA's new regulations are steps in the right
direction, but the overall process still has too many gaps that put the public
at risk. Our report can be viewed as a piece to continue the initiative's
modernizing and strengthening."